Project Grant R21AI186807
- This $564,001 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research on membrane-associated RING CH (MARCH) proteins and their role in restricting HIV-1 infection. MARCH proteins are a family of ubiquitin ligases that regulate membrane receptors and have been shown to restrict HIV-1 and other retroviruses by blocking viral envelope incorporation into budding virions. The research foundation for the State University of New...
- This federal Project Grant award of $2,505,639.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the interactions between primate lentivirus capsids (such as HIV-1, HIV-2, and SIVs) and the nuclear pore complex protein NUP358. The research aims to establish the molecular-level details of these interactions and how they affect viral nuclear import...
- This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to better understand the molecular mechanisms of HIV spread through cell-cell contact across a virological synapse (VS). The $515,282 award will enable Case Western Reserve University (CWRU) to develop a novel flow cytometry assay for quantifying and purifying infected cell-target cell pairs, and leverage...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) aims to develop strategies to prevent or eliminate unwanted immune responses toward adeno-associated virus (AAV)-delivered anti-HIV broadly neutralizing antibodies (bNAbs). The $887,626 award to the University of Miami will fund a 2-year study that enrolls 10 rhesus monkeys to test the efficacy of immunomodulatory drugs, such as rapamycin and ibrutinib, in inducing...
- This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 to support research focused on "Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells". The research aims to develop a multi-factor gene editing strategy to modify human hematopoietic stem and progenitor cells, enabling greater than 90% deletion of the CCR5 receptor and up to 50% allelic knock-in of inhibitory...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $142,908 to the San Diego Biomedical Research Institute to conduct research on how antibody glycosylation influences natural killer (NK) cell activation and antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The key objectives are to: 1) Determine how monoclonal antibody glycosylation profiles affect signaling protein...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $687,489 Project Grant to The Ohio State University under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study how the cytoplasmic tail domain of the HIV-1 envelope glycoprotein (Env) impacts Env trafficking and viral transmission. The project aims to understand the mechanisms by which a truncated Env variant confers resistance to entry inhibitors and enhances cell-to-cell viral transmission. The...
CHARACTERIZATION OF A NEW CXCR4-SPECIFIC RESTRICTION FACTOR - ABSTRACT HIV STRAINS VARY CONSIDERABLY IN BOTH GENETIC AND PHENOTYPIC FEATURES, BUT ALL VARIANTS USE CD4 AS THE PRIMARY RECEPTOR AND CONSEQUENTIALLY CD4+ T CELLS ARE THE MAJOR TARGET FOR VIRAL INFECTION. HOWEVER, VARIANTS MAY USE TWO DISTINCT CO-RECEPTORS, CCR5 AND/OR CXCR4 TO FACILITATE STEPS IN THE ENTRY PROCESS SUBSEQUENT TO CD4 BINDING. BOTH CCR5-USING VIRUSES (R5 VIRUSES) AND CXCR4-USING VIRUSES (X4 VIRUSES) ARE OFTEN PRESENT DURING CHRONIC AND LATER STAGES OF HIV INFECTION, BUT NEW INFECTIONS ARE ALMOST ALWAYS SEEDED BY R5 VIRUSES. THE HOST FACTORS THAT CONTRIBUTE TO THIS TRANSMISSION BOTTLENECK MAY HOLD CLUES TO HOST BIOLOGICAL DETERMINANTS OF HIV RISK, BUT THESE FACTORS HAVE REMAINED ELUSIVE. WE HAVE IDENTIFIED A HOST GENE EXPRESSED IN CD4+ T CELLS THAT RESTRICTS X4 VIRUS REPLICATION AND ENHANCES R5 VIRUS REPLICATION. THUS, THIS GENE, SLC35A2, REGULATES HIV INFECTION IN A MANNER THAT MIRRORS WHAT IS OBSERVED DURING TRANSMISSION. THIS IS THE FIRST EXAMPLE OF A GENE THAT SPECIFICALLY RESTRICTS X4 VIRUS INFECTION. BECAUSE THIS GENE WAS ONLY RECENTLY DISCOVERED, ITS ROLE IN INFECTION IN MUCOSAL CD4+ T CELLS, WHICH ARE PARTICULARLY IMPORTANT IN SEXUAL HIV TRANSMISSION, HAS NOT BEEN DEFINED. WE PROPOSE HERE TO EXAMINE THE EFFECT OF SLC35A2 ON R5 VERSUS X4 VIRUS INFECTION IN PRIMARY MUCOSAL CD4+ T CELLS USING BOTH SINGLE VIRUS INFECTIONS AS WELL AS VIRUS COMPETITION EXPERIMENTS. OUR PROPOSED EXPERIMENTS WILL ALSO TEST THE HYPOTHESIS THAT SLC35A2, WHICH IS A TRANSPORTER OF UDP-GALACTOSE AND THUS PLAYS A ROLE IN GLYCOSYLATION, ACTS THROUGH THE CORECEPTOR EARLY IN THE VIRAL LIFECYCLE, DURING FUSION. THESE PROPOSED HIGH-RISK, HIGH-PAY OFF STUDIES HAVE THE POTENTIAL TO REVEAL A UNIQUE ROLE FOR SLC35A2 IN HIV TRANSMISSION BIOLOGY AND ADDRESS A LONG-STANDING PUZZLE IN THE FIELD - NAMELY WHY ARE R5 VIRUSES SELECTED FOR TRANSMISSION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $220.0k | 7/15/25 | ||
| Not listed | $237.6k | 7/31/24 |